IR Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
The Zacks Consensus Estimate for Ingersoll Rand's second-quarter earnings has remained steady in the past 30 days. The company has an impressive earnings surprise history, having outperformed the consensus estimate in two of the preceding four quarters, matching on one occasion and missing once, the average surprise being 2.2%.
The consensus estimate for revenues is pegged at $1.84 billion, indicating growth of 2.1% from the prior-year quarter's figure. However, the consensus estimate for adjusted earnings is pinned at 80 cents per share, indicating a 3.6% decline from the year-ago quarter's number.
Let's see how things have shaped up for IR this earnings season.
Factors to Note Ahead of IR's Results
IR's Industrial Technologies & Services (IT&S) segment is anticipated to have performed well in the second quarter, driven by higher orders across its product portfolio of industrial vacuums and blowers, compressors and power tools. We anticipate the segment's revenues to increase 0.3% year over year to $1.47 billion.
The Precision and Science Technologies segment's results are expected to benefit from solid momentum in the life sciences business, driven by growth in short-cycle orders and multi-year contract wins for the production of legacy space suits. We expect the segment's revenues to increase 12.4% year over year to $380.9 million.
Ingersoll Rand has been making continued investments to support growth in demand generation and the Industrial Internet of Things, which are expected to have driven its performance. Also, the company's solid product portfolio, innovation capabilities and focus on boosting aftermarket businesses are other tailwinds for it.
Synergistic gains from the acquisitions made by IR are expected to have boosted revenues. In February 2025, the company acquired SSI Aeration, Inc., integrating it into the IT&S segment. The buyout enhanced Ingersoll Rand's ability to offer integrated low-pressure compressor and aeration solutions. The acquisitions of Air Power Systems Co., LLC ('APSCO'), Blutek s.r.l. (Blutek) and UT Pumps & Systems Private Limited (UT Pumps) in October 2024 strengthened the company's market position and technology portfolio across energy-efficient bulk handling, high-specification projects and pump technologies.
In June 2024, Ingersoll Rand acquired ILC Dover, integrating it into the Precision & Science Technologies segment. This acquisition enhanced the company's capabilities, with ILC Dover's single-use solutions for biopharma and pharma production complementing its expertise in liquid handling technologies and positive displacement pumps.
However, increasing costs of sales are likely to have weighed on IR's performance. Rising selling and administrative expenses are expected to have dented the company's margins and profitability. For the quarter under review, we anticipate Ingersoll Rand's adjusted EBITDA margin to be 26.6%, indicating a decline of 80 basis points on a year-over-year basis.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for IR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: IR has an Earnings ESP of -0.75% as the Most Accurate Estimate is pegged at 79 cents per share, which is lower than the Zacks Consensus Estimate of 80 cents. You can uncover the best stocks before they're reported with our Earnings ESP Filter.
Zacks Rank: IR presently carries a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here.
Stocks to Consider
Here are some companies within the broader Industrial Products sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Parker-Hannifin Corporation PH has an Earnings ESP of +0.23% and a Zacks Rank of 3 at present. The company is slated to release fourth-quarter fiscal 2025 (ended June 2025) results on Aug. 7.
Parker-Hannifin's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 4.5%.
Eaton Corporation plc ETN has an Earnings ESP of +0.33% and a Zacks Rank of 3 at present. The company is scheduled to release second-quarter 2025 results on Aug. 5.
Eaton's earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 1.9%.
Emerson Electric Co. EMR has an Earnings ESP of +0.46% and a Zacks Rank of 3 at present. The company is slated to release third-quarter fiscal 2025 (ended June 2025) results on Aug. 6.
Emerson's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Emerson Electric Co. (EMR): Free Stock Analysis Report
Parker-Hannifin Corporation (PH): Free Stock Analysis Report
Eaton Corporation, PLC (ETN): Free Stock Analysis Report
Ingersoll Rand Inc. (IR): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
13 minutes ago
- CTV News
Humpy Wheeler, the ‘P.T. Barnum of motorsports,' dies at 86
H.A. "Humpy" Wheeler, president and general manager of Lowe's Motor Speedway, pays up for being late to the news conference to announce the burnout contest that will be held during the pre-race show before the start of the NASCAR Sprint All-Star Race during a new conference at Lowe's Motor Speedway on April 22, in Concord, N.C. (AP Photo/Rick Havner) CHARLOTTE, N.C. — Humpy Wheeler, a pioneering motorsports promoter and former president and general manager of Charlotte Motor Speedway, has died, NASCAR said. He was 86. Charlotte Motor Speedway said Wheeler died of natural causes Wednesday in Charlotte, surrounded by his family. ADVERTISEMENT 'Humpy Wheeler was a visionary whose name became synonymous with promotion and innovation in our sport,' said NASCAR chairman Jim France. 'During his decades leading Charlotte Motor Speedway, Humpy transformed the fan experience through his creativity, bold ideas and tireless passion. His efforts helped expand NASCAR's national footprint, cement Charlotte as a must-visit racing and entertainment complex.' Howard Augustine Wheeler Jr. was born in 1938 in Belmont, North Carolina, and gained his first major publicity job with Firestone Tire and Rubber Company. He held several other positions after Firestone shut down its racing program in 1970 and was hired at Charlotte Motor Speedway by owner Bruton Smith as president in 1975. He became a transformative figure in promoting racing and was known as the 'P.T. Barnum of motorsports' for flashy pre-race stunts, elaborate productions and sparing no expense in ensuring fans had the most enjoyable experience possible at his events. Wheeler earlier this year was named winner of NASCAR's prestigious Landmark Award for Outstanding Contributions to NASCAR, to which he'd have been inducted into the Hall of Fame next year. 'Humpy's contributions to and accomplishments in NASCAR are without parallel. The breadth and depth of his legacy, and those whom he influenced, assisted and mentored, cannot be overstated,' said Winston Kelley, executive director of the Hall of Fame. 'Frequently adding new dynamics to the sport, Humpy's visionary leadership and creativity helped shape today's fan experience. 'Through his innovative promotions and stunts, Wheeler's contributions expanded NASCAR's national and international presence during the 1990s and early 2000s, solidifying Charlotte as 'NASCAR's Home for Racing.'' Wheeler mentored 'hundreds, if not thousands,' of people throughout his life, Kelley said, including inaugural NASCAR Hall of Famer Dale Earnhardt and Landmark Award recipient Janet Guthrie. Wheeler spent 33 years running Charlotte Motor Speedway. His innovation and pre-race extravaganzas recreated numerous military operations — including the invasion of Grenada — that made the facility a gold standard in NASCAR. He promoted school-bus races during the week, grassroots series for young aspiring racers, stunts and even the 'Robosaurus,' a towering, fire-breathing, car-crunching mechanical robot. Wheeler and his boss, the late Smith, grew Charlotte Motor Speedway into the ownership group Speedway Motorsports Inc., which acquired multiple race tracks that play a pivotal role in American motorsports today. Charlotte was the first track to build condominiums on site, built a restaurant overlooking the race track and was the first speedway of its size to install lights for night racing. 'Charlotte Motor Speedway was blessed to have a leader in Humpy Wheeler who can only be described as ONE of a kind,' the speedway said in a statement. ' For more than 30 years, Humpy was a promoter's promoter at Charlotte Motor Speedway. Alongside our founder Bruton Smith, Humpy pushed the speedway to new and greater heights — establishing the famed 1.5-mile superspeedway as not only the most innovative facility in NASCAR for fan, partner and competitor amenities, but also one of the most progressive in all of sports. 'Humpy's engaging smile and flair for promotion were legendary, and his impact on every stakeholder in motorsports will be long-lasting. Humpy not only made his mark with publicity, but also with a laser-focus toward the fans,' the speedway continued. 'He would often tell his staff to pay attention to 'the three Ts — tickets, traffic and toilets,' in order to ensure fans have the best possible experience. He would also say it was our job to put a little 'technicolor in people's black-and-white lives.'" Wheeler retired from Charlotte Motor Speedway and Speedway Motorsports in 2008 after a bitter falling out with Smith, but remained active in motorsports through his own consulting company and was on the voting panel for the NASCAR Hall of Fame. He is survived by his wife, Pat; daughters, Traci and Patti; son, Trip; and four grandchildren. Funeral arrangements are pending and the family request donations be made in Wheeler's name to the Belmont Abbey College Motorsports Management Program, which Wheeler was instrumental in launching more than 20 years ago. ___ Jenna Fryer, The Associated Press
Globe and Mail
13 minutes ago
- Globe and Mail
FDA Extends Review Period of REGN's Submission for Eylea HD
Regeneron Pharmaceuticals, Inc. ( REGN ) announced that the FDA has extended the target action dates for Eylea HD (aflibercept) injection 8 mg regulatory submissions. Eylea HD is the higher dose of Eylea. The regulatory body has now extended the target action dates to the fourth quarter of 2025 for two regulatory submissions for Eylea HD (aflibercept) Injection 8 mg. The submission includes a Chemistry, Manufacturing and Controls Prior-Approval Supplement for the Eylea HD prefilled syringe and a supplemental biologics license application seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications. Despite the extension announcement, REGN shares were up 3.4%. This information was previously communicated by the company during its second-quarter earnings release. This is probably because Eylea HD remains available in the United States through vial administration. Regeneron's shares have lost 17% year to date against the industry 's gain of 3.8%. More on REGN's Eylea HD The FDA extended the review periods after determining that the information submitted following a recent inspection of a third-party manufacturer constituted a major amendment to each application. The anticipated delay resulted from observations during an FDA general site inspection of Catalent Indiana LLC, which Novo Nordisk A/S ( NVO ) acquired in December 2024. Novo Nordisk submitted a comprehensive response in early August 2025 to address the observations noted by the FDA. Eylea HD is approved with dosing intervals every 8 to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every 8 to 12 weeks for patients with diabetic retinopathy, following three initial monthly doses. Eylea HD (known as Eylea 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG ( BAYRY ). While Regeneron holds exclusive rights to Eylea and Eylea HD in the United States, BAYRY holds the exclusive marketing rights outside the country. REGN and BAYRY equally share the profits from sales of Eylea and Eylea HD. REGN Banks on Eylea HD and Dupixent for Growth Regeneron's performance in the second quarter was encouraging. The company has finally managed to post revenue growth despite declining sales of lead drug Eylea. Eylea sales continue to decline due to competition from Vabysmo. To counter the decline in Eylea sales, Regeneron has developed a higher dose of the drug. Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand. REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi ( SNY ) records global net product sales of Dupixent. SNY and REGN are working to expand the drug's label further. The FDA had earlier approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Consistent label expansions of Dupixent continue to fuel its sales and help REGN earn higher profits. REGN is looking to strengthen its oncology portfolio to diversify its revenue stream. The recent progress with its oncology pipeline has been encouraging. The approval of Lynozyfic is a boost for its oncology portfolio. Zacks Rank Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Globe and Mail
13 minutes ago
- Globe and Mail
Nutriband (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity. The opioid crisis has reshaped how regulators approach pain management solutions. The most promising opportunities exist at the intersection of proven therapeutic benefit and enhanced safety mechanisms, requiring both technological innovation and regulatory expertise to navigate complex approval… Read More>> About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire San Francisco, CA 415.949.5050 Office Editor@ BioMedWire is powered by IBN
